abrdn Life Sciences Investors (NYSE:HQL) Stock Price Up 1.3% – What’s Next?

abrdn Life Sciences Investors (NYSE:HQL)’s stock price shot up 1.3% on Monday . The stock traded as high as $17.20 and last traded at $17.1050. 122,893 shares were traded during trading, an increase of 4% from the average session volume of 118,200 shares. The stock had previously closed at $16.89.

abrdn Life Sciences Investors Stock Up 0.2%

The stock’s fifty day moving average price is $16.99 and its 200 day moving average price is $14.91.

abrdn Life Sciences Investors Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, January 12th. Shareholders of record on Friday, November 21st will be paid a $0.50 dividend. The ex-dividend date is Friday, November 21st. This represents a $2.00 dividend on an annualized basis and a yield of 11.6%. This is an increase from abrdn Life Sciences Investors’s previous quarterly dividend of $0.42.

Institutional Trading of abrdn Life Sciences Investors

Institutional investors and hedge funds have recently modified their holdings of the stock. Geneos Wealth Management Inc. increased its position in abrdn Life Sciences Investors by 200.1% during the 2nd quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock valued at $29,000 after buying an additional 1,529 shares in the last quarter. Cornerstone Advisors LLC acquired a new position in shares of abrdn Life Sciences Investors during the third quarter valued at about $175,000. Samalin Investment Counsel LLC purchased a new position in shares of abrdn Life Sciences Investors in the 1st quarter valued at approximately $259,000. Stephens Inc. AR raised its position in shares of abrdn Life Sciences Investors by 9.8% in the 2nd quarter. Stephens Inc. AR now owns 21,231 shares of the company’s stock valued at $272,000 after purchasing an additional 1,895 shares during the last quarter. Finally, KPP Advisory Services LLC boosted its stake in abrdn Life Sciences Investors by 7.7% in the 2nd quarter. KPP Advisory Services LLC now owns 23,555 shares of the company’s stock worth $302,000 after purchasing an additional 1,681 shares in the last quarter. Institutional investors own 32.21% of the company’s stock.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.